Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Dipeptidyl Peptidase (DPP)

Omarigliptin

  Cat. No.:  DC7585   Featured
Chemical Structure
1226781-44-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
MK-3102 (MSD) is a novel DPP-4 Inhibitor, which improves glycaemic control with low risk of symptomatic hypoglycaemia.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1226781-44-7
Chemical Name: Omarigliptin
Synonyms: MK－3012;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3...;MK-3102;Omarigliptin;Omarigliptin (MK3102);(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-tetrahydro-2H-pyran-3-amine;MK3102;UNII-CVP59Q4JE1;CVP59Q4JE1;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine;Omarigliptin [USAN:INN];AK170357;Tube;OMARIGLIPTIN;OMARIGLIPTIN;MK-3102Omarigliptin?;MK-3102Omarigliptin?;CHEBI:134735;CHEBI:134735;OMARIGLIPTIN [WHO-DD];OMARIGLIPTIN [WHO-DD];AKOS025289528;AKOS025289528;MKMPWKUAHLTIBJ-ISTRZQFTSA-N;MKMPWKUAHLTIBJ-ISTRZQFTSA-N;NSC-802900;NSC-802900;NSC802900;NSC802900;AC-28992;AC-28992;OMARIGLIPTIN [INN];OMARIGLIPTIN [INN];CHEMBL2105762;CHEMBL2105762;(2R,3S,5R)-2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)PYRROLO[3,4-C]PYRAZOL-5(2H,4H,6H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE;(2R,3S,5R)-2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)PYRROLO[3,4-C]PYRAZOL-5(2H,4H,6H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE;J-690074;J-690074;HY-15981;HY-15981;NS00073001;NS00073001;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methanesulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)oxan-3-amine;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methanesulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)oxan-3-amine;OMARIGLIPTIN [MI];OMARIGLIPTIN [MI];Omarigliptin (JAN/USAN/INN);Omarigliptin (JAN/USAN/INN);2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-(2,6-dihydro-2-(methylsulfonyl)pyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-, (2R,3S,5R)-;2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-(2,6-dihydro-2-(methylsulfonyl)pyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-, (2R,3S,5R)-;s8565;s8565;BDBM50003020;SCHEMBL827590;BDBM50003020;1226781-44-7;SCHEMBL827590;2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-, (2R,3S,5R)-;1226781-44-7;Omarigliptin (MK-3102);2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-, (2R,3S,5R)-;EX-A395;Omarigliptin (MK-3102);D10317;EX-A395;GTPL8402;D10317;AM85511;GTPL8402;DTXSID70153678;AM85511;DS-7574;DTXSID70153678;CCG-268634;DS-7574;MFCD22573261;CCG-268634;OMARIGLIPTIN [JAN];MFCD22573261;PB39113;OMARIGLIPTIN [JAN];(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine;PB39113;NCGC00480770-01;Q21098979;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(m...
SMILES: S(C([H])([H])[H])(N1C([H])=C2C(C([H])([H])N(C2([H])[H])[C@@]2([H])C([H])([H])O[C@]([H])(C3C([H])=C(C([H])=C([H])C=3F)F)[C@]([H])(C2([H])[H])N([H])[H])=N1)(=O)=O
Formula: C17H20F2N4O3S
M.Wt: 398.4275
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over allproteases tested (IC50 > 67 μM).IC50 value: 1.6 nM [1]Target: DPP-4 inhibitorin vitro: Omarigliptin has weak ion channel activity (IC50 > 30 μM at IKr, Cav1.2, and Nav1.5). An expansive selectivity counterscreen (168 radioligand binding or enzymatic assays) was carried out at MDS Pharma. An IC50 > 10 μM was obtained in all assays. in vivo: When orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test (OGTT), it significantly reduced blood glucose excursion in a dose-dependent manner from 0.01 mg/kg (7% reduction in glucose AUC) to 0.3 mg/kg (51% reduction).
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC8875 Saxagliptin Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM and Ki of 1.3 nM.
DC7585 Omarigliptin MK-3102 (MSD) is a novel DPP-4 Inhibitor, which improves glycaemic control with low risk of symptomatic hypoglycaemia.
DC1105 Linagliptin (BI-1356) Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia